A new era for radiolabeled antibodies in cancer?

Sally J. Denardo, Linda A. Kroger, Gerald L Denardo

Research output: Contribution to journalReview articlepeer-review

67 Scopus citations


Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.

Original languageEnglish (US)
Pages (from-to)563-569
Number of pages7
JournalCurrent Opinion in Immunology
Issue number5
StatePublished - Oct 1 1999

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'A new era for radiolabeled antibodies in cancer?'. Together they form a unique fingerprint.

Cite this